NeuroVive Obtains U.S. Orphan Drug Designation for Traumatic Brain Injury
CEO Michael Bronnegard comments: "The U.S. Orphan Drug Designation for NeuroSTAT® was granted for patients with both open and closed traumatic brain injury, which exceeded our expectations. It indicates that there is indeed a significant medical need in this group of patients, where no effective pharmaceutical treatment is yet available to treat acute neurodegenerative injuries. Obtaining Orphan status in the U.S. is an important milestone in our company's efforts to develop an effective drug for acute brain injuries and this designation can facilitate more rapid development and commercialization in the United States."
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.